CASES Insights Into HER2+ Breast Cancer 2020

Perspectives on current treatment practices regarding HER2+ metastatic breast cancer, management of progressive HER2+ metastatic disease, and attitudes toward recently introduced and upcoming agents

July 16, 2020
Purchase Report

Faculty Chair

Joyce A. O’Shaughnessy MD

Texas Oncology-Baylor Charles A. Sammons Cancer Center, TX, US

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

Insights on the following breast cancer therapies were obtained

  • HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, HDAC inhibitors, chemotherapies
  • HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, neratinib, AIs, mTOR inhibitors, chemotherapies
  • TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan, GPNMB), immunotherapy, chemotherapies

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • A moderated virtual roundtable discussion focusing on treatment of metastatic breast cancer was held in July 2020
  • The group of advisors comprised 33 community oncologists
  • Data collection was accomplished through use of audience response system questioning and moderated discussion

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.